<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148044">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01979887</url>
  </required_header>
  <id_info>
    <org_study_id>195263-007</org_study_id>
    <nct_id>NCT01979887</nct_id>
  </id_info>
  <brief_title>Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory study to evaluate endpoints used to characterize participants with
      and without meibomian gland dysfunction (MGD) and will evaluate the correlation between
      signs and symptoms of MGD. No investigational drug will be administered in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Meibum Quality Score in the Study Eye as Assessed by the Investigator Using a 4-Point Scale</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Meibomian Glands</condition>
  <arm_group>
    <arm_group_label>Non-MGD Participants</arm_group_label>
    <description>Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild-Moderate MGD Participants</arm_group_label>
    <description>Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe MGD Participants</arm_group_label>
    <description>Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Meibum Expression</intervention_name>
    <description>Meibum expression as per protocol. No investigational drug is administered in this study.</description>
    <arm_group_label>Non-MGD Participants</arm_group_label>
    <arm_group_label>Mild-Moderate MGD Participants</arm_group_label>
    <arm_group_label>Severe MGD Participants</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tears
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants characterized as with or without Meibomian Gland Dysfunction.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Participants characterized as with or without Meibomian Gland Dysfunction.

        Exclusion Criteria:

          -  Lid heating therapy, therapeutic gland expression, or meibomian gland probing within
             12 months of enrollment

          -  Contact lens use in the 30 days prior to enrollment

          -  Lid hygiene within 48 hours prior to enrollment

          -  Use of eye makeup within 8 hours of enrollment

          -  Eyelash growth-stimulating products within 30 days prior to enrollment

          -  Use of systemic vitamins and/or systemic supplements containing omega 3 fatty acids
             within 60 days of enrollment

          -  Use of systemic anti-histamines within 30 days prior to enrollment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
